The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients.
Marica MeroniMiriam LongoErika PaoliniAnna AlisiLuca MieleEmilia Rita De CaroGiuseppina PisanoMarco MaggioniGiorgio SoardoLuca Vittorio ValentiAnna Ludovica FracanzaniPaola DongiovanniPublished in: Cancers (2021)
In sum, the rs599839 A>G variant is associated with protection against dyslipidemia and CVD in NAFLD patients, but as one it might promote HCC development by modulating SORT1 and PSRC1 expressions which impact on lipid metabolism and cell proliferation, respectively.